SkyOak Wealth’s Neumora Therapeutics NMRA Stock Holding History

SkyOak Wealth’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-150,000	Closed	-$293K	–	266
2026 Q1	$293K	Buy	150,000 +50,000	+50%	+$130K	0.05%	183
2025 Q4	$179K	Hold	100,000	–	–	0.03%	243
2025 Q3	$182K	Hold	100,000	–	–	0.03%	242
2025 Q2	$73.3K	Buy	+100,000	New	+$75.8K	0.01%	241
2025 Q1	–	Sell	-20,000	Closed	-$212K	–	262
2024 Q4	$212K	Buy	20,000 +5,000	+33%	+$59.9K	0.05%	233
2024 Q3	$198K	Hold	15,000	–	–	0.04%	226
2024 Q2	$147K	Buy	+15,000	New	+$155K	0.03%	232

Other funds holding NMRA

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SkyOak Wealth's NMRA Position: Q2 2026 in Review

SkyOak Wealth sold out of Neumora Therapeutics (NMRA) in Q2 2026, closing a stake of 150,000 shares — an estimated $293K sold.

SkyOak Wealth first reported a position in NMRA in Q2 2024 and held it in 7 quarters. The position peaked at $293K in Q1 2026. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

SkyOak Wealth reported no remaining Neumora Therapeutics position as of Q2 2026 after selling out during the quarter.
SkyOak Wealth sold 150,000 Neumora Therapeutics shares in Q2 2026, an estimated $293K.
SkyOak Wealth first reported a position in Neumora Therapeutics in Q2 2024 and held it in 7 quarters.
SkyOak Wealth's Neumora Therapeutics position peaked at $293K in Q1 2026.
113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on SkyOak Wealth's 13F filing for Q2 2026, filed 30 Jul 2026.